Global Healthcare Shake-Up: Drug Prices, Deals, and Disruptions

Recent developments in health news highlight major shifts as drugmakers delay European launches due to U.S. pricing pressures. Eli Lilly's $7.8 billion deal with Centessa targets sleep disorder treatments, while the FDA issues liver injury warnings connected to Amgen's drug, and activist investors urge changes at Teladoc Health.

In a series of significant shifts across the global healthcare landscape, drugmakers delay the European launch of new medicines amid U.S. pricing policies prompting concerns. Eli Lilly's recent $7.8 billion deal with Centessa marks a step towards diversifying its treatment portfolios to include sleep disorders. UK-based Centessa is developing groundbreaking therapies targeting orexin, a key molecule regulating the brain's sleep-wake cycle, with impactful treatments for narcolepsy currently underway.

Meanwhile, the FDA has highlighted potential risks associated with Amgen's drug, addressing liver injury cases in patients and warning healthcare providers to act promptly. In technological advancements, Butterfly Network has secured FDA clearance for an AI ultrasound tool designed to improve maternal care access.

Activist investor Pineal Capital engages with Teladoc Health's board, advocating cost savings and strategic changes. These moves, coupled with drug market pricing shifts, regulatory actions, and transformative deals, underscore the evolving pressures and opportunities within the healthcare industry.

(With inputs from agencies.)